News Novartis facing Gilenya generics again as Supreme Court lift... Novartis' hopes that the Supreme Court would protect its big-selling multiple sclerosis drug Gilenya from generic competition have been dashed.
Views & Analysis Increasing access to medicines: A critical look at pharmaceu... Extending patents is restricting patients’ access to the treatments they need.
News Lilly grabs first-ever FDA nod for a sleep apnoea drug Lilly's Zepbound has become the first drug approved by the FDA for obese patients with obstructive sleep apnoea, which affects millions in the US.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.